sST2 Biomarker Level in Acute/Chronic Coronary Syndrome After Revascularization

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The role of soluble circulating suppression of tumorigenicity 2 biomarker (sST2) in the ischemic heart disease patient is a debatable point. Therefore the aims of this study are to assess the plasma level of sST2 in ischemic heart disease patients versus non-ischemic ones, the acute changes in its level after percutaneous coronary intervention (PCI) and its relation to the severity of ischemia.
Epistemonikos ID: 08d161ae3c2d1d44dbefa2796054f283d83b6e47
First added on: May 14, 2024